Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: stem cell-based therapeutics - Pluristem Therapeutics

Drug Profile

Research programme: stem cell-based therapeutics - Pluristem Therapeutics

Alternative Names: Placenta expanded mesenchymal cells; Placental-derived mesenchymal stem cells; PLX-BMP; PLX-BMT; PLX-I; PLX-IBD; PLX-Immune; PLX-MS; PLX-ORTHO; PLX-PAH; PLX-STROKE

Latest Information Update: 14 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pluristem Life Systems
  • Developer Berlin-Brandenburg Center for Regenerative Therapies; Hebrew University of Jerusalem; New York University School of Medicine; Pluristem Therapeutics; Texas A&M University; United Therapeutics Corporation
  • Class Analgesics; Anti-inflammatories; Cardiovascular therapies; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Multiple sclerosis; Musculoskeletal disorders; Myocardial infarction; Preeclampsia; Pulmonary arterial hypertension; Pulmonary fibrosis; Stroke
  • No development reported Diabetic foot; Haematological malignancies; Heart failure; Inflammatory bowel diseases; Neuropathic pain; Pain; Parkinson's disease

Most Recent Events

  • 14 Feb 2018 Preclinical development is underway in Preeclampsia, Musculoskeletal disorders, Myocardial infarction, Pulmonary fibrosis, Multiple sclerosis and Pulmonary hypertension (Pluristem Therapeutics website, February 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in Europe (IM)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top